Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
05 April 2024 - 11:00PM
Business Wire
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused
on developing first-in-class and best-in-class targeted cancer
therapies, today announced that it will present preclinical data
for IM-3050, the company’s lead lutetium-177 radioligand therapy
(RLT) targeting fibroblast activation protein (FAP). Jack Higgins,
PhD, Chief Scientific Officer at Immunome, will present the data in
a poster at the American Association for Cancer Research (AACR)
Annual Meeting 2024, which is taking place April 5-10 in San Diego,
California.
“FAP is an attractive target for cancer therapy, but trials with
first-generation FAP-RLTs have produced modest clinical responses,
indicating the need for novel agents with improved therapeutic
properties,” commented Dr. Higgins. “We believe IM-3050 has
best-in-class potential and look forward to sharing preclinical
data for the program at AACR.”
Immunome expects to submit an Investigational New Drug
application to the U.S. Food & Drug Administration for IM-3050
in the first quarter of 2025.
Poster Presentation Details:
Title: A novel lutetium-177 radioligand therapy targeting
FAP has potent antitumor activity in xenograft cancer model
(Abstract #6026)
Presenter: Jack Higgins, PhD, Chief Scientific
Officer
Date: April 9, 2024 1:30 p.m. – 5:00 p.m. PDT
A copy of the poster will be available on the Events &
Presentations section of Immunome’s website following the
conference.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including small molecules, ADCs, RLTs and immunotherapies.
We believe that pursuing underexplored targets with appropriate
drug modalities leads to transformative therapies. Our proprietary
memory B cell hybridoma technology allows for the rapid screening
and functional characterization of novel antibodies and targets.
For more information, visit www.immunome.com or follow us on
Twitter and LinkedIn.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this communication regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995 (the “PSLRA”). We use words and
phrases such as “would,” “will,” “indicating,” “believe,”
“potential,” “look forward,” “expect” and similar expressions to
identify these forward-looking statements that are intended to be
covered by the safe-harbor provisions of the PSLRA. These
forward-looking statements include, but are not limited to,
statements regarding Immunome’s belief about the need for novel
agents with improved therapeutic properties and the potential for
IM-3050 and Immunome’s expected timeline for filing an IND for
IM-3050 in the first quarter of 2025; and other statements
regarding management’s intentions, plans, beliefs, expectations or
forecasts for the future. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. Such forward-looking statements are based on Immunome’s
beliefs and expectations and involve risks and uncertainties;
consequently, actual results may differ materially from those
expressed or implied in the statements due to a number of factors,
including, but not limited to, the risk that Immunome will not be
able to realize the benefits of its strategic transactions,
Immunome’s ability to grow and successfully execute on its business
plan, including the development and commercialization of its
pipeline; changes in the applicable laws or regulations; the
possibility that Immunome may be adversely affected by other
economic, business, and/or competitive factors; the risk that
regulatory approvals for Immunome’s programs and product candidates
are not obtained, are delayed or are subject to unanticipated
conditions; the risk that pre-clinical data may not be predictive
of clinical data; the risk that interim results of a clinical trial
do not necessarily predict final results; potential delays in the
commencement, enrollment and completion of clinical trials and the
reporting of data therefrom; the risk that our product and
development candidates fail to achieve their intended endpoints;
the complexity of numerous regulatory and legal requirements that
Immunome needs to comply with to operate its business; the reliance
on Immunome’s management; the prior experience and successes of the
Immunome’s management team not being indicative of any future
success; uncertainties related to Immunome’s capital requirements
and Immunome’s expected cash runway; the failure to obtain,
adequately protect, maintain or enforce Immunome’s intellectual
property rights; and other risks and uncertainties indicated from
time to time described in exhibit 99.2 filed with Immunome’s
Current Report on Form 8-K filed with Securities and Exchange
Commission (“SEC”) on February 13, 2024, and in Immunome’s Annual
Report on Form 10-K for the year ended December 31, 2023 filed with
the SEC on March 28, 2024, and in Immunome’s other filings with the
SEC. Immunome cautions that the foregoing list of factors is not
exclusive and not to place undue reliance upon any forward-looking
statements which speak only as of the date made. Moreover, Immunome
operates in a very competitive and rapidly changing environment.
New risks emerge from time to time. Except as required by law,
Immunome does not undertake any obligation to update publicly any
forward-looking statements for any reason after the date of this
press release to conform these statements to actual results or to
changes in their expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240405536897/en/
Immunome Contact: Max Rosett Interim Chief Financial
Officer and EVP, Operations investors@immunome.com
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From Apr 2024 to May 2024
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From May 2023 to May 2024